Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Regulatory Toxicology and Pharmacology : RTP
|
June 27, 2012
Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials
Joel P Bercu, David G Dolan
Regulatory Toxicology and Pharmacology : RTP
|
August 28, 2012
Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance
Joel P Bercu, Rizwan Sharnez, David G Dolan
American Journal of Epidemiology
|
June 24, 2005
Underascertainment of deaths using social security records: a recommended solution to a little-known problem
Jeanine M Buchanich, David G Dolan, Gary M Marsh, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 31, 2015
Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds
Brad Stanard, David G Dolan, William Hanneman, et al.
Journal of Occupational and Environmental Medicine
|
February 10, 2004
A 50-year historical cohort mortality study of workers in a pharmaceutical plant
David G Dolan, Ada O Youk, Gary M Marsh, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 29, 2016
Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation
Janet Gould, Courtney M Callis, David G Dolan, et al.
Regulatory Toxicology and Pharmacology : RTP
|
August 16, 2005
Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations
David G Dolan, Bruce D Naumann, Edward V Sargent, et al.
Regulatory Toxicology and Pharmacology : RTP
|
November 24, 2024
Considerations and derivations of permitted daily exposure limits for impurities from intravitreal pharmaceutical products
Yi Yu Rice, David G Dolan, Suren B Bandara, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 20, 2026
Derivation of an Occupational Exposure Limit (OEL) for a Potent Bispecific Protein-Blinatumomab (BLINCYTO®)
David G Dolan, Hansen L Wong, Fiona A Chandra, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 29, 2016
Using default methodologies to derive an acceptable daily exposure (ADE)
Ellen C Faria, Joel P Bercu, David G Dolan, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Regulatory Toxicology and Pharmacology : RTP
|
June 27, 2012
Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials
Joel P Bercu, David G Dolan
Regulatory Toxicology and Pharmacology : RTP
|
August 28, 2012
Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance
Joel P Bercu, Rizwan Sharnez, David G Dolan
American Journal of Epidemiology
|
June 24, 2005
Underascertainment of deaths using social security records: a recommended solution to a little-known problem
Jeanine M Buchanich, David G Dolan, Gary M Marsh, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 31, 2015
Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds
Brad Stanard, David G Dolan, William Hanneman, et al.
Journal of Occupational and Environmental Medicine
|
February 10, 2004
A 50-year historical cohort mortality study of workers in a pharmaceutical plant
David G Dolan, Ada O Youk, Gary M Marsh, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 29, 2016
Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation
Janet Gould, Courtney M Callis, David G Dolan, et al.
Regulatory Toxicology and Pharmacology : RTP
|
August 16, 2005
Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations
David G Dolan, Bruce D Naumann, Edward V Sargent, et al.
Regulatory Toxicology and Pharmacology : RTP
|
November 24, 2024
Considerations and derivations of permitted daily exposure limits for impurities from intravitreal pharmaceutical products
Yi Yu Rice, David G Dolan, Suren B Bandara, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 20, 2026
Derivation of an Occupational Exposure Limit (OEL) for a Potent Bispecific Protein-Blinatumomab (BLINCYTO®)
David G Dolan, Hansen L Wong, Fiona A Chandra, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 29, 2016
Using default methodologies to derive an acceptable daily exposure (ADE)
Ellen C Faria, Joel P Bercu, David G Dolan, et al.
Page
of 2